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Abstract
Nonmyeloablative allogeneic stem cell transplantation (SCT) can induce remission in patients with renal cell carcinoma
(RCC), but this graft-versus-tumor (GVT) effect is often accompanied by graft-versus-host disease (GVHD). Here, we
evaluated minor histocompatibility antigen (MiHA)-specific T cell responses in two patients with metastatic RCC who were
treated with reduced-intensity conditioning SCT followed by donor lymphocyte infusion (DLI). One patient had stable
disease and emergence of SMCY.A2-specific CD8+ T cells was observed after DLI with the potential of targeting SMCY-
expressing RCC tumor cells. The second patient experienced partial regression of lung metastases from whom we isolated a
MiHA-specific CTL clone with the capability of targeting RCC cell lines. Whole genome association scanning revealed that
this CTL recognizes a novel HLA-B7-restricted MiHA, designated ZAPHIR, resulting from a polymorphism in the splice donor
site of the ZNF419 gene. Tetramer analysis showed that emergence of ZAPHIR-specific CD8+ T cells in peripheral blood
occurred in the absence of GVHD. Furthermore, the expression of ZAPHIR in solid tumor cell lines indicates the involvement
of ZAPHIR-specific CD8+ T cell responses in selective GVT immunity. These findings illustrate that the ZNF419-encoded
MiHA ZAPHIR is an attractive target for specific immunotherapy after allogeneic SCT.
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Introduction
Allogeneic stem cell transplantation (SCT) has become the
treatment of choice for patients with various hematological
malignancies and some studies have also shown that metastatic
renal cell carcinoma (RCC) does respond to this therapy [1].
Several studies have explored allogeneic SCT after nonmyeloa-
blative or reduced intensity conditioning (RIC) with or without
donor lymphocyte infusions (DLI) as curative treatment for
metastatic RCC, and objective response rates varied from 0% to
53% [1–6]. However, substantial transplantation-related mortality
and toxicity due to graft-versus-host-disease (GVHD) has been
observed. Therefore, further development of allogeneic SCT for
solid tumors demands a more specific approach to selectively boost
graft-versus-tumor (GVT) reactivity without enhancement of
GVHD.
Minor histocompatibility antigens (MiHA) are the target
antigens of the GVT response, and expansion of MiHA-specific
cytotoxic T lymphocytes (CTL) usually precedes clinical remission
of the malignancy in patients treated with DLI [7–9]. However,
alloreactive CTL responses induced upon DLI generally lack
tumor specificity and are often accompanied by GVHD.
Therefore, it would be highly beneficial to direct T cell immunity
towards MiHA that are selectively expressed on malignant cells.
Only a few tissue-restricted MiHA have been described that are
aberrantly expressed on solid tumors, including HA-1, ECGF-1,
BCL2A1, LRH-1 and C19orf48 [10–14]. In addition to a MiHA,
an immunogenic antigen has been described expressed on
metastatic RCC, HERV-E which is derived from a human
endogenous retrovirus [15]. However, further characterization of
the target antigens of alloreactive T cells on RCC tumor cells is of
great importance for the development of specific post-transplant
immunotherapy for metastatic RCC.
Here, we characterized MiHA-specific T cell responses in two
patients with metastatic RCC treated with partial T cell-depleted
RIC-SCT followed by DLI. Presence of MiHA-specific CTL
targeting RCC tumor cells in vitro could be demonstrated in both
patients who experienced partial regression or stable disease
following RIC-SCT and DLI without clinical evidence of GVHD.
In one patient the T cell response was directed against the HLA-
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patient a MiHA-specific CTL clone emerged with the capability of
targeting RCC cell lines. We found that this CTL recognizes an
HLA-B7-restricted MiHA resulting from a polymorphism in the
splice donor site within the ZNF419 gene. This novel MiHA,
designated ZNF419 alternatively spliced polymorphic histocom-
patibility antigen in RCC (ZAPHIR), is co-expressed by RCC and
transformed B cells, but is not presented by non-hematopoietic
fibroblasts. Furthermore, ZAPHIR-specific CD8+ T cells were
detectable in peripheral blood post-transplant using tetramer
analysis. These findings exemplify that ZAPHIR represents a new
target antigen for the development of adjuvant immunotherapy for
RCC and hematological malignancies after allogeneic SCT.
Results
Assessing for alloreactive MiHA-specific CD8+ CTL after
transplantation of metastatic RCC patients
Four patients with progressive metastatic RCC after treatment
with at least one line of therapy were treated with RIC-SCT from
an HLA identical sibling donor (Table 1). These patients had
undergone tumor nefrectomy at a median of 4.9 years (range 2.8–
11.1 years) before transplantation. After RIC-SCT, all patients
reached eventually complete donor chimerism in the T cell
fraction. The first tumor evaluation in UPN677 at three months
after RIC-SCT showed stable disease, paralleled by expansion of
CD8+ T cells during tapering of cyclosporine A (CsA). One month
later this patient developed encephalopathy attributed to EBV-
reactivation. Following DLI, a second expansion of CD8+ T cells
as well as circulating EBV-specific CD8+ T cells was detected up
to 11 weeks using tetramers against the GLCTLVAML epitope.
At seven months after RIC-SCT a second DLI was administered
and the tumor in the abdomen remained stable without
occurrence of GVHD (Figure 1A). Evaluation of disease response
in UPN686 3 months after RIC-SCT showed partial regression of
pulmonary metastases that coincided with expansion of CD8+ T
cells during tapering of CsA and before the first DLI. This patient
received DLI at 3 months after RIC-SCT inducing a second
CD8+ T cell expansion and conversion to complete donor T cell
chimerism (Figure 1B). Three months later (i.e. 6 months after
RIC-SCT) CT-scan evaluation showed stable disease. Unfortu-
nately, this patient died from invasive fungal infection 9 months
after RIC-SCT. Post-mortal examination showed multiple histo-
logical-confirmed fungal lesions and two pulmonary metastasis
were found, but no signs of GVHD. Collectively, the chimerism
kinetics and expansions of CD8+ T cells in UPN677 and UPN686
indicated T cell alloreactivity, but episodes with infections may
have interfered.
To investigate whether MiHA-specific CD8+ T cells targeting
RCC tumor cells could be isolated from these two patients post
DLI-1, IFN-c+ CD8+ T cells (<2%) were sorted and weekly
restimulated with irradiated recipient peripheral blood mononu-
clear cells (PBMC) obtained pre-SCT. The resulting CD8+ T cell
lines, termed CTL line H (UPN677) and CTL line B (UPN686),
displayed significant IFN-c production against recipient EBV-
LCL, but not towards donor EBV-LCL, indicating the recognition
of a disparate MiHA (Figure S1). These data indicate that MiHA-
specific CD8+ T cells were present in vivo in RCC patients
UPN677 and UPN686 following allogeneic RIC-SCT and DLI.
Emergence of SMCY-specific CTLs in a RCC patient after
DLI
Next, we revealed TCR-Vb1+CD8+ cells to be the dominant T
cell population in CTL line H using TCR-Vb PCR and flow
cytometry (data not shown). Functional analysis showed that
specific IFN-c production by CTL line H was substantially
inhibited by anti-HLA class I and anti-HLA-A2 antibodies, but
not by antibodies against anti-HLA-B/C and anti-HLA class II
(Figure 2A). Furthermore, testing EBV-LCL from unrelated HLA-
A2+ individuals revealed that 3 out of 9 individuals were
recognized, which were all of male origin (Figure 2B). These
observations suggested that the dominant TCR-Vb1+CD8+ T
cells in CTL line H recognize an HLA-A2-restricted HY antigen.
Therefore, we stained CTL line H with PE- and APC-conjugated
tetramers for HLA-A2-restricted SMCY.A2 epitope FIDSYICQV
and found around 12.5% tetramer+ CD8+ T cells (Figure 2C).
These SMCY.A2 tetramer+ T cells confirmed to be TCR-Vb1+
by flow cytometry (data not shown). A greater than 95% pure
population of SMCY.A2 tetramer+ CTLs was isolated by flow
cytometry allowing further characterization of its cytotoxic
potential (Figure 2C). Flow cytometry-based cytotoxicity assays
revealed that the TCR-Vb1+ SMCY.A2 CTL induced high levels
of cytotoxicity against HLA-A2+ peptide-loaded SMCY- donor
EBV-LCL as well as SMCY+ recipient EBV-LCL (Figure 2D).
Tetramer analysis showed that SMCY.A2-specific CD8+ T cells
became detectable in vivo in the post-DLI setting, constituting
3.6%, 2.1% and 2.4% of the CD3+CD8+ T cell population
collected at week +24, +28 and +31, respectively (Figure 2E).
Collectively, these data show that SMCY.A2 CD8+ T cells
expanded in RCC patient UPN677 after DLI with the potential of
targeting SMCY-expressing RCC tumor cells in the absence of
GVHD.
Identification of a novel HLA-B7-restricted MiHA resulting
from a polymorphism in the splice donor site of ZNF419
TCR receptor analysis using PCR and flow cytometry showed a
predominant TCR-Vb4+CD8+ population in CTL line B, which
were sorted and cultured resulting in a pure population (data not
shown). This TCR-Vb4+CD8+ CTL, designated CTL B1,
mediated specific IFN-c production against recipient EBV-LCL,
but not towards donor EBV-LCL (Figure 3A). Release of IFN-c
could be completely inhibited by anti-HLA class I and anti-HLA-
B/C antibodies, but not by antibodies against anti-HLA-A2 and
anti-HLA class II (Figure 3A). Testing of EBV-LCL from
unrelated individuals sharing expression of HLA-B7 with the
recipient, and EBV-LCL from an HLA class I-mismatched
individual that were transduced with HLA-B*0702, revealed that
CTL B1 recognizes an HLA-B7-restricted MiHA (Figure 3B).
Next, we investigated whether the MiHA recognized by CTL
B1 was selectively expressed by hematopoietic cells. Therefore,
EBV-LCL, PHA-stimulated T cells and non-hematopoietic
fibroblasts from two MiHA+ HLA-B7+ healthy donors were used
as target cells. CTL B1 produced IFN-c upon co-culture with
EBV-LCL, whereas PHA-stimulated T cells and TNF-a/IFN-c
pre-treated bone marrow-derived fibroblasts were not recognized
(Figure 3C). In contrast, all target cell types were significantly
recognized by allo-HLA-B7 CTL, indicating their susceptibility to
CTL-mediated recognition (Figure 3C). To investigate whether
the MiHA targeted by CTL B1 is expressed by RCC tumor cells,
we performed flow cytometry-based cytotoxicity assay. We
observed that CTL B1 significantly targets the HLA-B7+ RCC
cell line SKRC33 and not SKRC18, showing MiHA mediated
cytotoxicity (Figure 3D). In addition to these RCC cell lines, CTL
B1 also recognizes and kills other solid tumor cell lines such as the
HLA-B7+ brain cancer cell line DAOY, but not pharynx cell line
FaDu. Allo-HLA-B7-specific CTL efficiently lysed all solid tumor
cell lines tested (Figure 3D).
ZAPHIR: RCC Associated Polymorphic Antigen
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the MiHA recognized by CTL B1, we performed whole genome
association scanning (WGAs). A total of 87 endogenous HLA-B7+
EBV-LCL were tested and 42 were recognized by CTL B1 (Figure
S2A). Comparing CTL recognition with SNP genotypes showed a
strong association for a clusterof 5 SNPs on chromosome19 (Figure
S2B). This genetic region included the ZNF419 gene which is
located at 19q13.43. There are 7 different splice variants of the
ZNF419 gene (Figure S3A-B), from which several are expressed by
patient UPN686 and its related donor (Figure S3C). To confirm
that the MiHA is encoded by the ZNF419 gene, we cloned the
different splice variants of the ZNF419 gene from both the donor
and recipient EBV-LCL. The various constructs were transiently
transfected into 293T-HLA-B*0702/ICAM/CD80 cells and tested
for CTL B1 recognition. CTL B1 efficiently recognized cells
transfected with a construct encoding an alternative ZNF419
isoform of the MiHA-positive recipient EBV-LCL (Figure 4A),
whereas none of the ZNF419 isoforms cloned from the donor EBV-
LCL stimulated IFN-c production by CTL B1 (data not shown).
Sequence analysis revealed that the recognized ZNF419 isoform
results from the A/G SNP rs2074071 located in the splicedonor site
involved inthejoining of exon 4 to intron4.Asa result ofthe G to A
substitution in the splice donor site, the alternative ZNF419
transcript of the recipient contains a disparate amino acid sequence
compared with that of the donor. By analyzing this disparate
sequence for HLA-B7 binding peptides using the NetMHC server,
we identified the strong HLA-B7 binding peptide IPRDSWWVEL
that is located over the exon4-intron4 boundary (Figure 4B). We
synthesized this 10-mer IPRDSWWVEL peptide (encoded by
rs2074071 A variant), the 9-mer IPRDSWWVE peptide and the 8-
mer IPRDSWWVEL peptide. We tested the HLA-B7 decamer
peptide IPRGSWWVEL that would be encoded by the G genotype
as well. In addition, we synthesized the HLA-B7 9-mer peptide
IPRGEWHGA that is located on the exon4-exon5 boundary of the
full length ZNF419 transcript. Their ability to stimulate IFN-c
release by CTL B1 upon loading of synthetic peptide on donor
EBV-LCL was tested and only the IPRDSWWVEL epitope was
recognized (Figure 4C). Flow cytometry analysis of CTL B1 showed
that only the tetramer containing the 10-mer peptide was positive as
opposed to tetramers containing the 8-, or 9-mer peptide
(Figure 4D). These data demonstrate that the 10-mer peptide
IPRDSWWVEL is the naturally presented epitope that is
recognized by CTL B1. Based on these findings, we designated
this novel MiHA as ZAPHIR for ZNF419 alternatively spliced
polymorphic histocompatibility antigen in RCC, which is the result
of a polymorphism in a splice donor site.
Expression of ZNF419 in various (malignant) hematopoietic and
non-hematopoietic cell samples was performed by microarray
gene expression analysis. Analysis of primary hematopoietic tissues
(Figure 5A) show that the overall expression of the gene is low, as is
the case for hematopoietic malignancies (Figure 5B). Although
fibroblast, keratinocytes, proximal tubular epithelial cells (PTEC)
and RCC show low expression levels as well, the keratinocytes
show an upregulation of ZNF419 when cultured in the presence of
IFN-c (Figure 5C).
Detection of ZAPHIR-specific CD8+ T cells in vivo
Next, we determined the rate of ZAPHIR disparity in HLA-B7-
matched SCT donor-recipient pairs using a competitive allele-specific
PCR. In 98 donor-recipient pairs (including RCC patient UPN686),
we identified 13 ZAPHIR-positive patients (i.e. 13.3%) that had
received a transplant from a ZAPHIR-negative donor. To detect
ZAPHIR-specific CD8
+T cells in these mismatched patients in vivo,w e
constructed an HLA-B7 tetramer using the 10-mer peptide
IPRDSWWVEL. First, we analyzed PBMCs samples of RCC patient
UPN686 from which the ZAPHIR-specific CTL B1 was isolated. In
addition, specific detection of ZAPHIR-tetramer
+ CD8+ T cells was
assessed after in vitro stimulation of PBMC samples with peptide-pulsed
donor EBV-LCL. At fourteen weeks post-SCT (i.e. pre-DLI) ,0.01%
ZAPHIR-tetramer
+ cells could be directly detected in the PBMC
sample, but after stimulation the percentage increased to 0.26% within
the total CD8+ T cell population (Figure 6A). Interestingly, the
percentage ZAPHIR-tetramer
+ CD8+ T cells increased at 4 weeks
after DLI to a level of 0.11%, and persisted at a low frequency
(,0.01%) up to 20 weeks post-DLI. In vitro stimulation resulted in an
increase of ZAPHIR-specific CD8+ T cells up to 1.37% for week 4,
0.46% for week 9, and 0.70% for week 20 post-DLI (Figure 6A). These
data show that ZAPHIR-specific CD8+ T cells with the capability of
targeting RCC metastases emerged in RCC patient UPN686 following
SCT and DLI in the absence of GVHD.
Specific detection of ZAPHIR-tetramer
+ CD8+ T cells was also
performed in the peripheral blood of 12 additional ZAPHIR-
mismatched patients. In 1 of these 12 patients, chronic myeloid
leukemia (CML) patient UPN 539, 0.04% and 0.36% ZAPHIR-
tetramer+ CD8+ T cells could be detected in the in vitro-stimulated T
cell cultures obtained from PBM Cs a m p l e sa t7a n d4 0w e e k sp o s t -
Table 1. Patient characteristics, GVHD, DLI and outcome.
Patient UPN651 UPN677 UPN705 UPN686
Age/Sex 57/M 53/M 60/M 49/M
Histology Clear cell Papillary Clear cell Clear cell
Metastases Lung and
mediastinum
Soft tissue Lung, lymph node, thyroid,
soft tissue
Lung
Previous therapy IFN-a IL-2, G250 mAb and RT
(2 courses)
IFN-a with 6 Retinoic acid
and resection of metastases
IL-2, IFN-a, 5FU (2 courses)
and DC vaccination
GVHD acute no no Grade II no
GVHD chronic limited no na no
DLI(x10
8T cells/kg) no 0.1 and 0.7 no 0.1
Outcome PD, died from meningo-encephalitis
during dexamethasone (5 months)
SD, died from CMV-pneumonitis
(8.5 months)
ne, died from multi-organ
failure (1.3 months)
PR, died from invasive fungal
infection (8.8 months)
Abbreviations: IFN-a, interferon-a; IL-2, interleukin-2, G250 mAb, monoclonal antibody against G250; RT, radiotherapy; 5FU, 5-fluorouracil; GVHD, graft-versus-host-
disease; DLI, donor lymphocyte infusion; PD, progressive disease, SD stable disease; na, not applicable; ne, not evaluated; PR partial remission.
doi:10.1371/journal.pone.0021699.t001
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directly in the PBMC (Figure 6B). Furthermore, ZAPHIR-specific
CTL could be cloned from PBMC collected 40 weeks post-therapeutic
DLI (Figure S4). These data indicate that ZAPHIR-specific CD8+ T
cell responses can also be detected in transplanted CML patients.
Discussion
MiHA are considered to play a dominant role in mediating
GVT reactivity after HLA-identical allogeneic SCT for both
hematological malignancies and solid tumors. Especially MiHA
Figure 1. Longitudinal follow-up of CD8+ T cells in peripheral blood from metastatic RCC patients UPN677 and UPN686 in relation
to clinical outcome. (A) UPN677: percentages of recipient T cells (right y axis) are compared with CD8+ T cell count610
6 per liter peripheral blood
(left y axis). Administration of SCT and DLI 1–2 are indicated by m and ., respectively. Treatment interval with CsA is shown by the dotted line. Time
points of confirmed EBV infection, occurrence of EBV-specific T cells (depicted as % from total CD8+ T cell population) and death are indicated. (B)
UPN686: for legend see (A). Time points of confirmed candidemia and death are indicated.
doi:10.1371/journal.pone.0021699.g001
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promising targets to boost GVT reactivity without enhancing
GVHD. For the development of tumor-specific immunotherapy it
is important to enlarge the spectrum of molecularly identified
MiHA that are selectively expressed. In this study, we character-
ized antigens targeted by allogeneic donor T cells in metastatic
RCC patients treated with partial T cell-depleted RIC-SCT
followed by DLI. Using PBMCs collected from two patients,
showing either stable disease or partial response, we succeeded in
expanding CD8+ CTLs with the capability of targeting MiHA
expressed by RCC cells. Interestingly, a TCR-Vb4+CD8+ CTL
targeting a novel HLA-B7-restricted MiHA, designated ZAPHIR,
was isolated from RCC patient UPN686 showing partial
regression of lung metastases in the absence of GVHD. Flow
cytometry-based cytotoxicity assays revealed that ZAPHIR-
specific CTL B1 mediated efficient lysis of HLA-B7+ RCC cell
lines. In addition, ZAPHIR-specific CTL also mediated cytotox-
icity against an HLA-B7+ brain tumor cell line. Furthermore,
while EBV-LCL were recognized by ZAPHIR-specific CTL,
PHA-stimulated T cells and cytokine-treated bone marrow (BM)-
derived fibroblasts did no induce IFN-c production. These data
indicate that the HLA-B7-restricted MiHA ZAPHIR is co-
expressed by solid tumors and transformed B cells. Notably,
emergence of ZAPHIR-specific CD8+ T cells in RCC patient
UPN686 as well as CML patient UPN 539 was observed in the
absence of GVHD. Microarray gene expression analysis of several
(malignant) hematopoietic cells and normal tissues show that
expression of ZNF419 is low. This might explain the absence of an
immune response, as is the case in vivo in non-malignant tissues,
and therefore no GVHD could be observed. However, as the
keratinocytes cocultured with IFNc show that under inflammatory
conditions ZNF419 is upregulated and could lead to an immune
response. Since the tumor tissues are surrounded by an
inflammatory environment, a GVT response mediated by
MiHA-specific T cells could occur in vivo.
In order to identify the novel MiHA recognized by CTL B1, we
used the WGAs method that was recently described by Van
Bergen et al [16]. This method makes use of the SNP-genotyping
of unrelated HLA-B7+ individuals who were divided in a MiHA+
and MiHA- group and yielded a highly specific genomic location
on chromosome 19q13.43. This led to the rapid identification of
ZNF419 as the gene of interest showing WGAs to be a very
suitable method for MiHA identification. Further analysis revealed
that the novel ZAPHIR epitope is located on the exon4-intron4
boundary which is the result of a G to A substitution in the splice
donor site leading to an alternative spliced ZNF419 variant. The
mechanism that MiHA immunogenicity can arise from alternative
splicing due to a single intronic SNP, has been previously
described for the MiHA ACC-6 [17].
In RCC patient UPN677, we demonstrated emergence of
SMCY.A2-specific CD8+ T cells after DLI without the clinical
manifestations of GVHD. Interestingly, Hambach et al. showed
that SMCY.A2-specific CTL are capable of efficiently targeting
solid tumor cells in a three-dimensional micro tumor model [11].
Therefore, our clinical findings suggest that emergence of
SMCY.A2 CTL may have played a role in stabilization of the
tumor growth after allogeneic SCT and DLI in patient UPN677.
Interestingly, high numbers of SMCY.A2 CD8+ T cells up to
3.6% of the total CD8+ T cell population in patient UPN677 did
not induce clinical signs of GVHD to either skin, liver or gut.
Earlier studies have shown that SMCY is ubiquitously expressed,
and SMCY-specific CTL responses have been associated with
GVHD [9,18–20]. However, GVHD is a multi-factorial disease
process to which many factors contribute, and we speculate that
lack of other inflammatory triggers prevented the development of
acute GVHD (reviewed by Ferrara et al [21]).
Currently, the role of allogeneic RIC-SCT for the treatment of
metastatic RCC patients is still unclear. New developments in
treatment of metastatic RCC have significantly changed the
treatment strategies for these patients. However, the novel drugs
that are currently used do not cure patients and the incidence of
complete remissions is low. Therefore, new strategies should
continue to be explored and the discovery of antigenic targets of
alloreactive T cells in transplanted RCC patients may allow the
development of tumor-specific post-transplantation strategies such
as vaccination or adoptive T cell transfer. Two earlier studies have
identified target antigens at the molecular level using CD8+ CTL
isolated from patients with metastatic RCC treated with allogeneic
SCT. Tykodi et al. identified an HLA-A*0201-restricted MiHA,
which is encoded by the C19orf48 gene located on chromosome
19q13 [14]. In addition, recognition of the non-polymorphic RCC
over-expressed human endogenous retrovirus type E (HERV-E)
antigen by alloreactive T cells was described by Takahashi et al
[15]. Not only tumor-specific MiHA are interesting for these
purposes, but also hematopoietic-restricted MiHA with aberrant
expression in solid tumor cells may be useful for this strategy.
Genotype frequency analysis in HLA-B7 allo-SCT couples
revealed a disparity rate of 13.3%, making the ZAPHIR MiHA
therapeutically relevant as is the case for the other, commonly
mismatched MiHA HA-1, LRH-1 and BCL2A1 [22–24].
Adoptive transfer of a single dose of HA-1 CTLs was effective in
eradicating disseminated solid tumors in a mouse model [11].
Therefore, adoptive immunotherapy with ex vivo-generated CTLs
directed against MiHA expressed by RCC might be an attractive
adjuvant approach as has also been studied in patients with
leukemia [25]. Alternatively, patients could be vaccinated with
peptides or DCs loaded with peptides or electroporated with
MiHA-encoding mRNA [26,27].
Figure 2. CD8+ T cells reactive with the SMCY.A2 peptide developed after DLI in RCC patient UPN677. (A) HLA-restriction was
determined by the production of IFN-c released by CTL line H upon stimulation with recipient EBV-LCL in the presence of HLA blocking antibodies.
Data are displayed as mean IFN-c release 6 SD of triplicate wells. (B) Production of IFN-c by CTL line H stimulated with EBV-LCL of 9 HLA-A2+
unrelated individuals, showing recognition of 3 out of 9 EBV-LCL of male origin. (C) Flow cytometry analysis of CD8+ CTL line H simultaneously
stained PE- and APC-conjugated SMCY.A2 tetramer, CD8 AlexaFluor 700, CD4, CD14, CD16 and CD19 FITC and Sytox Blue. CD8+ T cells were gated on
FITC- and Sytox Blue- cells. The percentage of SMCY.A2 tetramer-binding cells among viable CD8+ T cells was 12.6%. These SMCY.A2 tetramer+ CD8+
T cells were sorted and expanded resulting in a .95% pure population. (D) Survival of the recipient and donor EBV-LCL, and donor EBV-LCL pulsed
with peptide FIDSYICQV was determined in a flow cytometry-based cytotoxicity assay after incubation with SMCY.A2-specific CTL from patient
UPN677 (&), allo-HLA-A2 CTL (.; positive control) or medium only (N) at an E:T ratio of 3:1 in the presence of 25 U/ml IL-2. Data are depicted as
mean 6SD of triplicate wells. (E) Detection of SMCY.A2-specific CD8+ T cells in peripheral blood of RCC patient UPN677. PBMC collected 24, 28 and
31 weeks post DLI-1 were simultaneously stained with PE- and APC-conjugated SMCY.A2 tetramer, CD8 AlexaFluor 700, CD4, CD14, CD16 and CD19
FITC and Sytox Blue. Subsequently, cell populations were analyzed by flow cytometry. Cells were gated on CD8+FITC-Sytox Blue- lymphocytes, and
the percentage of tetramer-binding cells among CD8+ T cells is depicted.
doi:10.1371/journal.pone.0021699.g002
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T cell-depleted RIC-SCT followed by DLI in patients with
metastatic RCC. Our transplant procedure resulted in stable
engraftment, manageable GVHD and T cell responses in two
patients. SMCY-specific CD8+ T cells were identified in a patient
with stable disease, and CD8+ T cells targeting the novel HLA-B7-
restricted MiHA ZAPHIR in the second patient with a partial
response. Although the role of allogeneic RIC-SCT in RCC may
be limited in the near future, this study shows that the approach of
partial T cell-depleted SCT followed by DLI induces MiHA-
specific T cell responses potentially targeting RCC tumor cells.
The significance for cellular immunotherapy of the novel MiHA
ZAPHIR is demonstrated by the emergence of ZAPHIR-specific
CTL after allo-SCT, and its ex vivo cytotoxic activity against RCC
and transformed B cell lines. Furthermore, identification of the
antigenic targets of alloreactive T cells remains important for the
further understanding of the GVT response in different malig-
nancies and for development of strategies to selectively target
tumor cells after allogeneic SCT.
Materials and Methods
Patient eligibility
From December 2002 till August 2003, four consecutive
patients with metastatic RCC have been treated in our
transplantation program. The eligibility criteria for patients
included histological proven, clinically progressive metastatic
RCC, failure on earlier cytokine based systemic therapy and no
other curative treatment available. This study was approved by the
institutional review board of RUNMC, and all patients gave
written informed consent.
Conditioning regimen, GVHD prophylaxis and DLI
Patients received partial T cell-depleted RIC-SCT. The
conditioning regimen consisted of total lymph node irradiation
on each of three consecutive days followed by cyclophosphamide
50 mg/kg body weight intravenously on each of four consecutive
days (total dose 200 mg/kg bodyweight). Inguinal and femoral
lymph node regions were also irradiated. A total dose of 12 Gy was
delivered in 2 Gy fractions, twice daily, on three consecutive days.
Donors were HLA-identical siblings. Following T cell depletion,
CD3+ T cells were added back to generate a stem cell graft
containing a fixed number of 0.5610
6 T cells/kg body weight of
recipient. All patients received CsA 3 mg/kg/day by continuous
intravenous infusion from days -1 to +14. Thereafter CsA dose was
reduced to 2 mg/kg/day and continued until day 21, when CsA
was tapered off for 8–10 weeks.
Patients underwent CT-scan of abdomen and chest before, and
every 3 months after RIC-SCT to assess disease response. Patients
without acute GVHD grade .II, without chronic GVHD and
with persistent disease received DLI four weeks after discontinu-
ation of immunosuppression. If no GVHD occurred and residual
disease persisted, a second DLI was administered two months
later. The first DLI dose consisted of 0.1610
8 T cells/kg
bodyweight of the recipient, and the second DLI dose was
0.7610
8 T cells/kg.
Cell isolation and culture
CD8+ CTL lines H and B were isolated from PBMC obtained
one and three months after DLI-1, respectively, by weekly
stimulation with PBMC obtained before SCT in Iscove’s modified
Dulbecco’s medium (IMDM; Invitrogen, Carlsbad, CA) supple-
mented with 10% human serum (HS; Sanquin blood bank,
Nijmegen, the Netherlands). After initial stimulation, CTL line H,
CTL line B, the HLA-B7 alloreactive CTL Kor18 and the HLA-
A2 alloreactive CTL 1E2 (0.5*10
6) were cultured in IMDM/10%
HS containing irradiated (80 Gy) recipient EBV-LCL (0.5*10
6),
irradiated (60 Gy) allogeneic PBMC (0.5*10
6) from two donors,
100 IU/ml IL-2 (Chiron, Emeryville, CA) and 1 mg/ml PHA-M
(Boehringer, Alkmaar, the Netherlands). All cell lines and primary
cells were cultured in IMDM/10% fetal calf serum (FCS; Integro,
Zaandam, The Netherlands). Fibroblasts were cultured from BM
aspirates obtained from healthy stem cell donors. BM was
resuspended in 20 ml IMDM/20% FCS and incubated overnight
at 37uC in tissue culture flasks. The non-adherent fraction was
removed and fibroblasts were further cultured in IMDM/20%
FCS to passage 3 before analysis. T cell blasts were generated by
stimulating PBMC in IMDM/10% HS with 20 mg/ml PHA-M
for 3 days. Thereafter, PHA-activated T cells were washed and
further cultured with 100 IU/ml IL-2 for 2 additional days.
IFN-c secretion assay
IFN-c producing CTLs were detected and isolated using the
IFN-c secretion assay (Miltenyi Biotec). Briefly, 1610
6 CTLs were
incubated with 1610
6 irradiated (30 Gy) recipient EBV-LCL in a
total volume of 2 ml IMDM/10% HS. After 16 hours of
incubation at 37uC, cells were harvested, washed with PBS/
0.5% FCS and 5 mM EDTA, and labeled at a concentration of
10
8 cells/ml with 50 mg/ml Ab-Ab conjugates directed against
CD45 and IFN-c for 10 minutes on ice. Subsequently, cells were
diluted with IMDM/10% FCS at 1610
5 cells/ml and allowed to
secrete IFN-c for 45 minutes at 37uC. After the cytokine-capturing
period, cells were collected, resuspended at a concentration of 10
8
cells/ml in PBS/0.5% FCS/5 mM EDTA, and stained with 5 mg/
ml PE–conjugated anti-IFN-c mAb and FITC-conjugated
CD8 mAb for 20 minutes at 4uC. Finally, cells were analyzed
and sorted using an Epics Elite flow cytometer (Beckman Coulter).
Flow cytometry
PE- and APC-labeled SMCY.A2 tetramers containing peptide
FIDSYICQV and ZAPHIR.B7 tetramers containing peptide
IPRDSWWVE were produced as described previously [28]. PE-
labeled tetramer for the HLA-A2-restricted EBV peptide
GLCTLVAML were purchased from Beckman Coulter. PBMC
or CTL lines were incubated with 20 mg/ml tetramer for 15 min
at room temperature. After washing with PBS/0.5% bovine serum
albumin (BSA; Sigma,St Louis, MO, USA), cells were labeled with
Figure 3. Cytotoxicity of HLA-B7-restricted CTL B1 against RCC and hematological tumor cell lines. (A) HLA-restriction was determined
by the production of IFN-c released by CTL B1 upon stimulation with recipient EBV-LCL in the presence of HLA blocking antibodies. (B) Production of
IFN-c by CTL B1 stimulated with rt EBV-LCL, EBV-LCL of an unrelated individual (#2) sharing HLA-B7 with the recipient, and an EBV-LCL of an HLA
class I-mismatched individual (#3) that was transduced with HLA-B*0702. (C) Production of IFN-c by CTL B1 and allo-HLA-B7 CTL stimulated with
MiHA+ EBV-LCL and PHA-stimulated T cells and bone marrow-derived fibroblasts. Fibroblasts were pretreated with 10 ng/ml TNFa and 200 U/ml IFNc
for 2 days before coculture with CTL B1 (E:T ratio 10:1). (D) MiHA mediated cytotoxicity on the HLA-B7+ RCC cell lines SKRC33 (rs2074071 genotype
AA) and SKRC18 (rs2074071 genotype GG), the brain tumor cell line DAOY (rs2074071 genotype AG), and pharynx cell line FaDu (rs2074071 genotype
GG), in flow cytometry-based cytotoxicity assays was determined after incubation with CTL B1 (&), allo-HLA-B7 CTL (.; positive control) or medium
only (N) at an E:T ratio of 3:1 in the presence of 25 U/ml IL-2. Data are depicted as mean 6SD of triplicate wells.
doi:10.1371/journal.pone.0021699.g003
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production by CTL B1 upon stimulation with 293T-HLA-B*0702/ICAM/CD80 cells transfected with ZNF419 full length, cloned splice variant containing
the exon4/exon5 boundary and the alternative ZNF419 splice variant containing intron 4. (B) Schematic representation of the ZNF419 gene on
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with FITC-conjugated CD4, CD14, CD16 and CD19 (Beckman
Coulter) for 30 min at 4uC. Finally, cells were washed and
resuspended in PBS/0.5% BSA containing 0.2 mM Sytox Blue
(Invitrogen) marking dead cells and analyzed using the Cyan flow
cytometer (Beckman Coulter). Tetramer staining using both APC
and PE showed double positive events, allowing optimal
discrimination between background staining and positive cells.
All FITC-positive cells were gated into a dump channel and
played no role in further analysis.
Retroviral transduction of HLA-B*0702 in cell lines and
CTL stimulation assay
LZRS-HLA-B*0702-IRES-EGFP vector was used to generate a
stable producer cell line. Retroviral transduction was performed
using non-tissue culture-treated 35-mm
2 dishes (Becton Dickinson)
coated with 10 mg/ml retronectin (Takara Biomedicals, Shiga,
Japan). In brief, 10
6 target cells were resuspended in 2 ml virus
supernatant and transferred to retronectin-coated dishes. After
24 h of incubation, cells were collected and incubated with fresh
virus supernatant and used in CTL stimulation assays [29].
Release of IFNc was determined by ELISA (Pierce Endogen,
Rockford, IL).
Flow cytometry-based cytotoxicity studies
Flow cytometry-based cytotoxicity assays were performed as
previously described [30]. HLA-B7
+ cell lines were labeled with
2.5 mM carboxyfluorescein diacetate succimidyl ester (CFSE;
Molecular Probes Europe). Target cells (1610
4) were co-cultured
with unlabelled effector cells (3610
4) at an E:T ratio of 3:1 in a
total volume of 200 ml IMDM/10% FCS containing 25 U/ml IL-
2 in 96-wells flat-bottom plates. After 1–3 days of co-culture, cells
were harvested and 7-amino-actinomycin D (7AAD; Sigma-
Aldrich, St Louis, MO) was added. Numbers of viable target cells
were quantified by flow cytometry.
Whole Genome Association scanning (WGAs)
A panel of 87 HLA-B*0702 expressing EBV-LCL was selected
to perform WGAs. To test recognition of the EBV-LCL panel by
the T cell clone, triplicate samples of 6610
4 EBV-LCL were
thawed, washed and cultured for 2 days, and 5610
3 MiHA
specific T cells were added to each well. After 24 hours, culture
supernatant was used for IFN-c ELISA. Of each EBV-LCL, PCR-
free whole genome amplification was performed and analyzed by
Illumina Human1M-duo arrays containing probes for 1.1 million
SNPs (Illumina, San Diego, CA) [31]. EBV-LCL panel was
divided into MiHA
pos and MiHA
neg groups using 5 times the level
of IFN-c production in the absence of EBV-LCL as a threshold for
recognition. WGAs was performed by combining T cell
recognition with SNP-genotyping data. The level of matching
between both patterns was calculated according to Fisher’s exact
test.
Genotyping using KASPar system
Genotyping of the HLA-B7-matched SCT donor-recipient pairs
was conducted by KASPar (KBioscience, Herts, UK), a fluores-
chromosome 19q13.43. The nucleotide and deduced amino acid sequences of the alternatively and correctly spliced transcripts present in recipient
and donor, respectively, are shown. Disparity between the recipient and donor ZNF419 protein sequence is due to a G to A polymorphism in de
splice donor site of intron 4 leading to the ZAPHIR epitope (underlined). (C) ZAPHIR epitope reconstitution with synthetic peptides corresponding to
HLA-B7 10-mer peptide IPRDSWWVEL, 9-mer peptide IPRDSWWVE, 8-mer peptide IPRDSWWV, HLA-B7 10-mer peptide IPRGSWWVEL and HLA-B7 9-
mer peptide IPRGEWHGA. Donor EBV-LCL was pulsed with 10 mM peptide and tested for recognition by CTL B1 in the presence of 25 U/ml IL-2. Data
are displayed as mean 6 SD of triplicate wells. (D) Flow cytometry analysis of CTL B1 with tetramers containing the 8-, 9-, or 10-mer peptide. Cells
were stained with PE- and ACP-conjugated tetramer, CD8 AlexaFluor 700, CD4 FITC and Sytox Blue. Cells were analyzed by flow cytometry by gating
on CD8+CD4-Sytox Blue- lymphocytes. The percentage of tetramer+ cells among CD8+ T cells is depicted.
doi:10.1371/journal.pone.0021699.g004
Figure 5. ZNF419 microarray gene expression analysis of (malignant) hematopoietic and non-hematopoietic cells. (A) ZNF419
expression of various hematopoietic cell types isolated from PBMC. (B) ZNF419 expression of hematopoietic malignancies sorted for CD34, CD33, and
CD19/CD34. (C) ZNF419 expression of normal tissues +/2 IFNc. Data are displayed as MFIx10
6. 0–10= no expression, 10–100= low expression, 100–
1000= intermediate expression, .1000= high expression.
doi:10.1371/journal.pone.0021699.g005
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labeled primers. Details of the process and primer sequence of
SNP rs2074071 can be obtained from KBioscience.
Microarray gene expression analysis
Total RNA was isolated from various (malignant) hematopoietic
and non-hematopoietic cell samples using small and micro scale
RNAqueous isolation kits (Ambion, Inc., Austin, TX). Malignant
hematopoietic cell samples included CML, AML and ALL cells
isolated by flow cytometry based on expression of CD34, CD33,
and CD19/CD34, respectively. Non-malignant hematopoietic
cells included total PBMC, and B-cells, T-cells and monocytes
isolated from total PBMC by flow cytometry based on expression
of CD19, CD3 and CD14, respectively. In addition, hematopoi-
etic stem cells were isolated from G-CSF-mobilized peripheral
blood by flow cytometry based on expression of CD34. Non-
hematopoietic cell samples included cultured skin-derived fibro-
blasts, keratinocytes and PTEC (kindly provided by Dr. C. van
Kooten, Leiden, Netherlands). Finally, total RNA was isolated
from EBV-B cells, PHA-T blasts and RCC cell lines. (kindly
provided by Dr. E.M.E. Verdegaal, Leiden, Netherlands). RNA
samples were amplified for microarray gene expression analysis
using the Illumina TotalPrep RNA amplification kit (Ambion).
Briefly, total RNA was treated with DNase I using the TURBO
DNA-free kit (Ambion), and converted to cDNA by reverse
transcription. After purification of cDNA, cRNA was synthesized
by in vitro transcription. cRNA samples were prepared following
the whole-genome gene expression direct hybridization assay
(Illumina, Inc., San Diego, CA), and resuspended cRNA samples
were dispensed onto Human HT-12 v3 Expression BeadChips
(Illumina). Hybridization was performed in the Illumina hybrid-
ization oven for 17 hours at 58uC. Microarray gene expression
data were analyzed using Rosetta Resolver 7.2 gene expression
data analysis system.
Construction of full-length and truncated ZNF419
constructs
The full-length ZNF419 transcript in pCMV6-XL was obtained
by Origene, Rockville, MD (sc 316397). The different splice
variants of the ZNF419 transcript containing exon 1 to 5 and the
exon 4/intron 4 boundary were generated by RT-PCR of the
MiHA+ recipient and MiHA- donor EBV-LCL. The following
Figure 6. Detection of ZAPHIR-specific CD8+ T cells in peripheral blood of RCC patient UPN686 and CML patient UPN539. (A) PBMC
collected before DLI and 4, 9, and 20 weeks post DLI were stained with PE- and ACP-conjugated ZAPHIR/HLA-B7 tetramer, CD8 AlexaFluor 700, CD4,
CD14, CD16 and CD19 FITC and Sytox Blue. Cells were analyzed by flow cytometry by gating on CD8+FITC-Sytox Blue- lymphocytes. The percentage
of tetramer+ cells among CD8+ T cells is depicted. The remaining PBMCs were stimulated once with ZAPHIR peptide pulsed (10 mM) EBV-LCL of the
donor and assayed on day 7 for ZAPHIR-tetramer+ CD8+ T cells. (B) PBMC collected pre-DLI, 7 and 40 weeks post-DLI were stained and gated as
described under (A). The remaining PBMCs were stimulated once with ZAPHIR peptide-pulsed (10 mM) EBV-LCL of the donor and assayed on day 7 for
ZAPHIR-tetramer+ CD8+ T cells.
doi:10.1371/journal.pone.0021699.g006
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ZNF419-F 59-AAAGGTACCTCTACTCACAGGCTCCGAT-
GG-39 and ZNF419-R 59-AAACCTAGGGAGGTTGAAACGC-
TGGCTAAAG-39. These primers contained BamHI and KPNI
digestion sites. PCR products were purified from 1.5% agarose gel
using the Qiagen gel extraction kit, and cloned into vector
pcDNA3.1(+) (Invitrogen) using the BamHI and KPNI digestions.
Constructs were verified by sequencing, and used for transfection
into 293T-HLA-B*0702/ICAM/CD80 cells. In brief, 3*10
4
293T-HLA-B*0702/ICAM/CD80 cells were plated into poly-D-
lysine coated 96-wells flat bottom wells (Becton Dickinson,
Franklin Lakes, NY), cultured overnight at 37uC, and then
transfected with 200 ng plasmid DNA using lipofectamin reagent
(Invitrogen). Transfected cells were cultured for 2 additional days
and used in CTL stimulation assays.
Epitope prediction and epitope reconstitution assay
HLA-B7 binding peptides were predicted using the NetMHC
3.2 server (http://www.cbs.dtu.dk/services/NetMHC/). Peptides
were synthesized by Proimmune and dissolved in DMSO. Peptide
stock solutions were diluted in IMDM to a concentration of
1 mM. In peptide recognition assays, target cells were preincu-
bated with peptide for 1 hour in a volume of 1 ml prior to the
addition of CTL.
Supporting Information
Figure S1 Generation of MiHA-reactive CD8+ CLT lines
from patients with RCC after allogeneic RIC-SCT. (A)
Detection of IFN-c secreting CD8+ T cells in T cell lines
generated from patient UPN677 and UPN686 after co-culture
with EBV-LCL of the recipient. Stimulated T cells were stained
with PE-conjugated IFN-c detection reagent and FITC-conjugat-
ed anti-CD8 mAb, and analyzed by flow cytometry. (B)
Production of IFN-c by CTL lines H and B upon stimulation
with recipient (Rt) EBV-LCL, donor (Do) EBV-LCL or medium.
Data are displayed as mean IFN-c release 6 SD of triplicate wells.
(TIF)
Figure S2 WGAs using 87 HLA-B7 positive EBV-LCL
revealed a cluster of 5 SNPs to associate on chromosome
19 cluster of SNP. (A) Detection of IFN-c-secretion by CTL B1,
here depicted as OD450, upon stimulation with 87 HLA-B7+
EBV-LCL showed 42 EBV-LCL to be recognized. The threshold
for recognition was set at 5 times the level of IFN-c production in
the absence of EBV-LCL. (B) Detail of chromosome 19 showing
all SNP that cluster according to Fisher’s exact test. No other SNP
cluster was found at any other chromosome.
(TIF)
Figure S3 ZNF419 splice variant. (A–B) The full length
transcript of ZNF419 (NM_001098491) consists of 5 exons which
are spliced into an additional 6 splice variants (NM001098492
through NM_001098496 and NM_024691). Due to SNP
rs2074074 in the splice donor site an additional transcript occurs
in patient UPN686 which includes exon 4 (grey) leading to a stop-
codon (*). (C) The different splice variants that were expressed by
patient UPN686 and its related donor were amplified as a pool,
using the primerset as depicted (R) and cloned into pcDNA3.1(+).
(TIF)
Figure S4 Generation of ZAPHIR-reactive CD8+ CTL
Lines from CML patient UPN539 40 weeks post DLI. (A)
PBMC collected 40 weeks post DLI were sorted for TET+CD8+
T cells (inside square) and cloned into single cells. (B) Production
of IFN-c by ZAPHIR-specific CTL clones with ZAPHIR-peptide
pulsed donor EBV-LCL, donor EBV-LCL or medium. Data are
displayed as mean IFN-c release 6 SD of triplicate wells.
(TIF)
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